Are Mounjaro and Zepbound the same drug?

Both contain tirzepatide from the same manufacturer at the same strengths. They are approved for different indications: Mounjaro for type 2 diabetes, Zepbound for weight management and obstructive sleep apnoea.

Why do telehealth providers sell compounded tirzepatide rather than Mounjaro for weight management?

Mounjaro is not approved for weight management, and a cash-pay compounded preparation is cheaper than the approved products. The trade-off is that compounded preparations are not FDA-approved and were not tested in trials.

Published August 27, 2026 · updated August 27, 2026 · medically reviewed by Dr. S. Shuwart, MD on August 27, 2026

Medically reviewed · August 27, 2026

Mounjaro vs compounded tirzepatide

Mounjaro is tirzepatide approved for type 2 diabetes; compounded tirzepatide is a pharmacy preparation sold mostly for weight management. What the indication difference means, and how the products compare.

Mounjaro

Mounjaro is tirzepatide approved as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. It comes in single-dose pens and vials at 2.5 mg to 15 mg. The SURPASS trials, in people with type 2 diabetes, are its evidence base; weight reduction in those trials was substantial but smaller than in the SURMOUNT trials of people without diabetes, a pattern seen across the class.

Prescribing outside the indication

A clinician may lawfully prescribe an approved drug for a use not on its label; whether an insurer will pay for that is another matter, and many plans require a diagnosis of type 2 diabetes for Mounjaro coverage. For weight management the manufacturer’s approved product is Zepbound, with the same molecule and strengths. This site records which approved product a provider offers and does not describe one as a substitute for the other.

Compounded tirzepatide

A pharmacy preparation of the active ingredient, not FDA-approved, sold mostly for weight management through telehealth at prices below either approved product. It carries evidence grade C on this site; the approved products carry grade A. Everything on the Zepbound comparison page about dose delivery, evidence, regulation and price structure applies here.

For a patient with type 2 diabetes

Two things change. First, the diabetes indication may open insurance coverage for Mounjaro that a weight-management indication would not. Second, providers vary in whether they treat patients with type 2 diabetes at all and in what monitoring they require; the provider profile records eligibility criteria where the provider publishes them. Hypoglycaemia risk with insulin or sulfonylureas is a labelled warning for both tirzepatide products and is a reason the prescribing decision belongs with a clinician who knows the full medication list.

Questions this page answers

Are Mounjaro and Zepbound the same drug?: Both contain tirzepatide from the same manufacturer at the same strengths. They are approved for different indications: Mounjaro for type 2 diabetes, Zepbound for weight management and obstructive sleep apnoea.
Why do telehealth providers sell compounded tirzepatide rather than Mounjaro for weight management?: Mounjaro is not approved for weight management, and a cash-pay compounded preparation is cheaper than the approved products. The trade-off is that compounded preparations are not FDA-approved and were not tested in trials.

Sources

Mounjaro (tirzepatide) prescribing information (label)
Zepbound (tirzepatide) prescribing information (label)

Educational information, not medical advice. Decisions about GLP-1 medication belong with you and a licensed clinician who knows your history. Compounded medications are not FDA-approved. Report an error.